{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:27:08Z","timestamp":1750228028142},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00393-021-00973-w","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T14:03:55Z","timestamp":1615385035000},"page":"305-313","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glukokortikoidfreie und glukokortikoidarme Therapie der rheumatoiden Arthritis"],"prefix":"10.1007","volume":"80","author":[{"given":"Christoph","family":"Fiehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"973_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00393-016-0156-5","volume":"76","author":"K Albrecht","year":"2017","unstructured":"Albrecht\u00a0K et\u00a0al (2017) Versorgung der rheumatoiden Arthritis 2014. Aktuelle Daten aus der Kerndokumentation. Z\u00a0Rheumatol 76:50\u201357","journal-title":"Z Rheumatol"},{"key":"973_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht\u00a0K, Luque Ramos\u00a0A, Callhoff\u00a0J et\u00a0al (2018) Ambulante Versorgung und Krankheitslast der rheumatoiden Arthritis. Z\u00a0Rheumatol 77:102\u2013112","journal-title":"Z Rheumatol"},{"key":"973_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00393-019-0660-5","volume":"78","author":"K Albrecht","year":"2019","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Zink\u00a0A (2019) Langzeittrends in der rheumatologischen Versorgung. Z\u00a0Rheumatol 78:703\u2013712","journal-title":"Z Rheumatol"},{"key":"973_CR4","unstructured":"George\u00a0M, Baker\u00a0J, Winthrop\u00a0K, Wu\u00a0Q, Chen\u00a0L, Xie\u00a0F, Yun\u00a0H, Curtis\u00a0J (2019). Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol 71(suppl 10). https:\/\/acrabstracts.org\/abstract\/risk-of-serious-infection-with-long-term-use-of-low-dose-glucocorticoids-in-patients-with-rheumatoid-arthritis\/. Zugegriffen: 8\u00a0Mar 2021"},{"key":"973_CR5","unstructured":"Ocon\u00a0A, Reed\u00a0G, Kremer\u00a0J (2019) In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use [abstract]. Arthritis Rheumatol 71(suppl 10). https:\/\/acrabstracts.org\/abstract\/in-rheumatoid-arthritis-new-onset-prednisone-use-is-associated-with-a-daily-dose-cumulative-dose-and-duration-dependent-risk-for-cardiovascular-events-at-6-months-and-1-year-of-use\/. Zugegriffen: 8\u00a0Mar 2021"},{"issue":"3","key":"973_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1210\/en.2012-2045","volume":"154","author":"VSS Vandevyver","year":"2013","unstructured":"Vandevyver\u00a0VSS, Dejager\u00a0L et al (2013) New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 154(3):993\u20131007","journal-title":"Endocrinology"},{"key":"973_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3899\/jrheum.180668","volume":"46","author":"AL Ramos","year":"2019","unstructured":"Ramos\u00a0AL, Redeker\u00a0I, Hoffmann\u00a0F et al (2019) Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J\u00a0Rheumatol 46:564\u2013571","journal-title":"J Rheumatol"},{"issue":"Suppl. 2","key":"973_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et al (2018) S2e-Leitlinie zur Behandlung der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z\u00a0Rheumatol 77(Suppl. 2):35\u201353","journal-title":"Z Rheumatol"},{"key":"973_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00393-019-0668-x","volume":"78","author":"C Fiehn","year":"2019","unstructured":"Fiehn\u00a0C, Kr\u00fcger\u00a0K (2019) Therapiealgorithmus der rheumatoiden Arthritis. Z\u00a0Rheumatol 78:529\u2013539","journal-title":"Z Rheumatol"},{"key":"973_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bijlsma\u00a0JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"973_CR11","unstructured":"https:\/\/www.rheumatology.org\/Portals\/0\/Files\/Rheumatoid-Arthritis-Guideline-Project-Plan.pdf. Zugegriffen: 6. Dez. 2020"},{"key":"973_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","volume":"156","author":"MF Bakker","year":"2012","unstructured":"Bakker\u00a0MF, Jacobs\u00a0JWG, Welsing\u00a0PMJ et al (2012) Low-dose prednisone inclusion in a\u00a0methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med 156:329\u2013339","journal-title":"Ann Intern Med"},{"key":"973_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","volume":"388","author":"JWJ Bijlsma","year":"2016","unstructured":"Bijlsma\u00a0JWJ, Welsing\u00a0PMJ, Woodworth\u00a0TG et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a\u00a0multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343\u2013355","journal-title":"Lancet"},{"key":"973_CR14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/annrheumdis-2019-215304","volume":"78","author":"MM Verhoeven","year":"2019","unstructured":"Verhoeven\u00a0MM, de Hair\u00a0MJH, Janneke Tekstra\u00a0J (2019) Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U\u2011Act-Early and CAMERA-II treat-to-target trials. Ann Rheum Dis 78:1333\u20131338","journal-title":"Ann Rheum Dis"},{"key":"973_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","volume":"72","author":"J Detert","year":"2013","unstructured":"Detert\u00a0J, Bastian\u00a0H, Listing\u00a0J et al (2013) Induction therapy with adalimumab plus methotrexate for 24\u00a0weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-na\u00efve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72:844\u2013850","journal-title":"Ann Rheum Dis"},{"key":"973_CR16","unstructured":"Lund Hetland\u00a0M, Haavardsholm\u00a0E, Rudin\u00a0A, Nordstr\u00f6m\u00a0D, Nurmohamed\u00a0M, Gudbjornsson\u00a0B, Lampa\u00a0J, H\u00f8rslev-Petersen\u00a0K, Uhlig\u00a0T, Grondal\u00a0G, \u00d8stergaard\u00a0M, Heiberg\u00a0M, Twisk\u00a0J, Lend\u00a0K, Krabbe\u00a0S, Lindqvist\u00a0J, Ekwall\u00a0A, Lederballe Gr\u00f8n\u00a0K, Kapetanovic\u00a0M, Faustini\u00a0F, Tuompo\u00a0R, Lorenzen\u00a0T, Cagnotto\u00a0G, Baecklund\u00a0E, Hendricks\u00a0O, Vedder\u00a0D, Sokka-isler\u00a0T, Husmark\u00a0T, Ljos\u00e5\u00a0M, Brodin\u00a0E, Ellingsen\u00a0T, S\u00f6derbergh\u00a0A, Rizk\u00a0M, Reckner\u00a0\u00c5, Uhrenholt\u00a0L, Larsson\u00a0P, Just\u00a0S, Stevens\u00a0D, Laurberg\u00a0T, Bakland\u00a0G, Olsen\u00a0I, Vollenhoven\u00a0R van, NORD-STAR Study Group (2019) A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial [abstract]. Arthritis Rheumatol 71(suppl 10). https:\/\/acrabstracts.org\/abstract\/a-multicenter-randomized-study-in-early-rheumatoid-arthritis-to-compare-active-conventional-therapy-versus-three-biological-treatments-24-week-efficacy-and-safety-results-of-the-nord-star-trial\/. Zugegriffen: 8\u00a0Mar 2021"},{"key":"973_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl\u00a0C, Bijlsma\u00a0JW, De Wit\u00a0M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957","journal-title":"Ann Rheum Dis"},{"key":"973_CR18","first-page":"A-1154\/B-1939\/C","volume":"113","author":"C Fiehn","year":"2016","unstructured":"Fiehn\u00a0C, Herzer\u00a0P, Holle\u00a0J et al (2016) Klug entscheiden in der Rheumatologie. Dtsch \u00c4rztebl 113:A-1154\/B-1939\/C-1953","journal-title":"Dtsch \u00c4rztebl"},{"key":"973_CR19","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1002\/art.21421","volume":"52","author":"S Wassenberg","year":"2005","unstructured":"Wassenberg\u00a0S, Rau\u00a0R, Steinfeld\u00a0P, Zeidler\u00a0H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a\u00a0multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371\u20133380","journal-title":"Arthritis Rheum"},{"key":"973_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","volume":"396","author":"GR Burmester","year":"2020","unstructured":"Burmester\u00a0GR, Buttgereit\u00a0F, Bernasconi\u00a0C et al (2020) Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a\u00a0double-blind, multicentre, randomised controlled trial. Lancet 396:267\u2013276","journal-title":"Lancet"},{"key":"973_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/art.41232","volume":"72","author":"V Norvang","year":"2020","unstructured":"Norvang\u00a0V, Brinkmann\u00a0GH, Yoshida\u00a0K et al (2020) Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies. Arthritis Rheumatol 72:1072\u2013108121","journal-title":"Arthritis Rheumatol"},{"key":"973_CR22","unstructured":"Roubille\u00a0C, Coffy\u00a0A, Rincheval\u00a0N, Daures\u00a0J, Flipo\u00a0R, Dougados\u00a0M, Combe\u00a0B (2020) Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol 72(suppl 10). https:\/\/acrabstracts.org\/abstract\/ten-year-analysis-of-the-risk-of-severe-outcomes-related-to-very-low-dose-glucocorticoids-in-early-rheumatoid-arthritis\/. Zugegriffen: 8\u00a0Mar 2021"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00973-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-00973-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00973-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:21:31Z","timestamp":1671582091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-00973-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-00973-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"29 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Fiehn: Vortrags\u2011, Autoren- oder Beraterhonorare von AbbVie, BMS, Boehringer-Ingelheim, Celgene, Gilead, Janssen, Lilly, Novartis, MSD, Medac, Pfizer, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}